title: Neurophysiologic studies of patients with Crohn's disease on long-term treatment with metronidazole.
abstract: Fifty-three patients with Crohn's disease were chosen for this study. They were divided into three groups: the first group (19 patients) was treated with metronidazole and had been receiving the drug for at least 1 year; the second group (13 patients) had previously had the same type of long-term treatment but had been off the drug for at least 3 months before entering the study; the third group (21 patients) had never received treatment with metronidazole. The maximum daily dose of metronidazole used was 800 mg. All patients were examined with a broad set of neurophysiologic investigations devised to reveal signs of peripheral neuropathy. No significant difference was found between the three groups. The conclusion was that a daily dose of metronidazole not exceeding 800 mg is well tolerated by patients with Crohn's disease with regard to objective signs of neurotoxicity. A few patients from all three groups showed a raised perception threshold for changes of temperature in the feet (as compared with the department's normal standard). The results of the test were almost identical in the three groups and thus not connected with the metronidazole treatment. During the study, patients were asked about subjective neurologic symptoms such as tingling and numbness. A few patients from all three groups reported such paresthesias from time to time, but they were of a transient nature, not perpetual, and, in patients taking metronidazole, not aggravated despite continuing treatment with unchanged dose.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Dept. of Medicine, Karolinska Institute at Huddinge University Hospital, Sweden.
authors.forename: D
authors.initials: D
authors.lastname: Ståhlberg
authors.forename: F
authors.initials: F
authors.lastname: Bárány
authors.forename: K
authors.initials: K
authors.lastname: Einarsson
authors.forename: B
authors.initials: B
authors.lastname: Ursing
authors.forename: D
authors.initials: D
authors.lastname: Elmqvist
authors.forename: A
authors.initials: A
authors.lastname: Persson
mesh_terms: D000328:Adult; D000368:Aged; D003424:Crohn Disease / Q000188:drug therapy* / Q000503:physiopathology; D005071:Evoked Potentials / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000009:adverse effects*; D008875:Middle Aged; D009431:Neural Conduction / Q000187:drug effects; D010292:Paresthesia / Q000139:chemically induced; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D012677:Sensation / Q000187:drug effects
chemical_list: D008795:Metronidazole